{"id":714098,"date":"2024-09-23T08:34:01","date_gmt":"2024-09-23T08:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=714098"},"modified":"2024-09-23T08:34:01","modified_gmt":"2024-09-23T08:34:01","slug":"concerned-pet-owners-unite-to-address-serious-adverse-effects-of-librela-and-monoclonal-antibodies-in-veterinary-medicine","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/concerned-pet-owners-unite-to-address-serious-adverse-effects-of-librela-and-monoclonal-antibodies-in-veterinary-medicine_714098.html","title":{"rendered":"Concerned Pet Owners Unite to Address Serious Adverse Effects of Librela and monoclonal antibodies in Veterinary Medicine"},"content":{"rendered":"
\n
\"Concerned<\/a><\/div>\n
\n
Nikita<\/div>\n<\/div>\n<\/div>\n
Are monoclonal antibodies (i.e. Librela) Dangerous for Our Pets? While many veterinarians claim that Librela (bedinvetmab) has no side effects, numerous pet owners report serious adverse effects in their dogs, including paralysis and even death. We must raise awareness about these troubling experiences and advocate for the safety of our beloved pets. It’s time to take action to prevent further harm.<\/div>\n

A growing number of pet owners are raising alarm over the serious side effects associated with Librela, a medication prescribed for pain relief in dogs affected by osteoarthritis. Reports from numerous owners worldwide indicate that their pets have experienced severe symptoms, including neurological issues and paralysis, after receiving this treatment.<\/p>\n

Nikita, a beloved cane corso from Italy, is among those affected. Following her first and only Librela injection, her health rapidly declined, leading to paralysis in her hind legs and an inability to stand or urinate independently. These symptoms have prompted her owner to seek answers and share experiences with other concerned pet owners through social media platforms.<\/p>\n

Research has indicated that Nerve Growth Factor (NGF), which Librela inhibits, plays a crucial role in the body’s nervous, immune, and endocrine systems. Despite claims of minimal side effects, many dogs have developed serious health issues after treatment.<\/p>\n

“Pet owners are feeling helpless and desperate,” said Valeria Rubino, a concerned pet owner and advocate. “We’re sharing our stories to raise awareness and prevent further suffering among our pets.”<\/p>\n

Many users in online support groups have reported similar experiences, with some pets recovering partially after detoxification, while others faced tragic outcomes. The consensus is clear: There is an urgent need for increased scrutiny of veterinary medications, especially those that have a history of causing adverse effects in human medicine.<\/p>\n

Call to Action<\/strong><\/p>\n

We urge regulatory bodies, including the FDA, to revisit the approval processes for veterinary drugs, ensuring they are subjected to the same rigorous standards as human medications. It is imperative to prioritize the safety and well-being of our pets over corporate interests.<\/p>\n

Pet owners are encouraged to share their experiences, contact their veterinarians for alternative treatments, and advocate for greater transparency and research into the medications prescribed to their beloved companions.<\/p>\n

Together, we can work toward ensuring that no pet suffers needlessly from preventable side effects of medications like Librela.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> SNW<\/a>
Contact Person:<\/strong> Paula Diamond
Email:<\/strong> Send Email<\/a>
Country:<\/strong> United States
Website:<\/strong> www.successnews.world<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Nikita Are monoclonal antibodies (i.e. Librela) Dangerous for Our Pets? While many veterinarians claim that Librela (bedinvetmab) has no side effects, numerous pet owners report serious adverse effects in their dogs, including paralysis and even death. We must raise awareness … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,451,406,404,416],"tags":[],"class_list":["post-714098","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Law-Legal","category-Pharmaceuticals-Biotech","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/714098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=714098"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/714098\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=714098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=714098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=714098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}